Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

Stock Information for Surface Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Surface Oncology Inc.

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
TScan Therapeutics Announces Positive Updated Data from the ALLOHA(TM) Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA(TM) Phase 1 Trial and Future Market Opportunities
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
TScan Therapeutics to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.